BioNTech Downgraded to Market Perform with $113 Target After 24% Rally
Leerink Partners downgraded BioNTech to Market Perform from Outperform and set a $113 price target after its stock rallied 24% from December lows of $92, outpacing the biotech index. The firm cited alignment with discounted cash flow valuation and highlighted BioNTech’s $20.3 billion cash position supporting its oncology pipeline.
1. Rating Adjustment and Valuation Alignment
On February 2, Leerink Partners lowered BioNTech’s rating to Market Perform from Outperform and set a $113 price target, bringing valuation in line with its discounted cash flow model.
2. Recent Stock Rally
BioNTech’s shares surged 24% from December lows at $92 to reach $113, outperforming the 4% gain of the S&P Biotechnology Select Industry over the same period.
3. Oncology Pipeline and Cash Position
The company holds $20.3 billion in cash to fund its oncology pipeline, including the VEGFA/PD-L1 bispecific pumitamig partnership with Bristol Myers Squibb and Fast Track status for BNT113 in HPV16+ head and neck cancer. Kylie Jimenez joined the management board as Chief People Officer to support the oncology expansion.